Moderna provided updates on key elements of its pipeline, including a next-generation COVID-19 vaccine, an RSV vaccine, a new seasonal flu, and a combination seasonal flu/COVID vaccine. Moderna ...
Moderna lost more than 20% of its value on the stock market as the company delivered slashed revenue guidance for 2025, stressing savings as key to its goal of balancing cash flow by 2028.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback